Peptides DB

Research-centric peptide and protocol reference hub

GHK-Cu vs PE 22-28

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

GHK-Cu: Research use — not FDA-approvedPE 22-28: Research use — not FDA-approved

A data-driven comparison of GHK-Cu and PE 22-28 (also searched as PE 22-28 vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

GHK-Cu centers on skin, while PE 22-28 leans toward metabolic. On indexed research, GHK-Cu is ahead (GHK-Cu: 5 studies, Preclinical; PE 22-28: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • GHK-Cu is strongest for skin; PE 22-28 for metabolic.
  • Evidence: GHK-Cu Preclinical (5 studies) vs PE 22-28 Human evidence (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
GHK-CuPE 22-28

At a glance

GHK-CuPreclinical

Copper Peptide | Skin Regeneration & Anti-Aging Compound

Strongest: SkinStudies: 5Level: Well Studied
PE 22-28Human evidence

TREK-1 Channel Blocker | Shortened Spadin Analog

Strongest: MetabolicStudies: 5Level: Emerging

GHK-Cu vs PE 22-28: side-by-side

MetricGHK-CuPE 22-28
ClassSkinCognitive
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman evidence
Studies indexed55
Research levelWell StudiedEmerging
Strongest effectSkin & aestheticsMetabolic & appetite
Healing & recovery4.02.0
Muscle & body comp1.00.0
Metabolic & appetite3.04.0
Neuro & mood2.03.0
Sleep & circadian0.00.0
Inflammation & immune4.02.0
Skin & aesthetics5.00.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyGHK-CuPE 22-28
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling
RouteTopical / subcutaneous

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

What is PE 22-28?

### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.

Full PE 22-28 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingGHK-Cu4.0/5 effect signal
MuscleGHK-Cu1.0/5 effect signal
MetabolicPE 22-284.0/5 effect signal
NeuroPE 22-283.0/5 effect signal
InflammationGHK-Cu4.0/5 effect signal
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack GHK-Cu and PE 22-28?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

GHK-Cu vs PE 22-28: side effects

GHK-Cu
  • improved skin texture18
  • localized irritation5
  • transient tingling4
  • gi upset1
  • headache1
PE 22-28

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

GHK-Cu has 5 approved studies indexed (Preclinical), and PE 22-28 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is GHK-Cu or PE 22-28 better?

It depends on your goal. GHK-Cu is strongest for skin; PE 22-28 for metabolic. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.

Is GHK-Cu or PE 22-28 better for weight loss?

PE 22-28 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is GHK-Cu or PE 22-28 better for muscle?

GHK-Cu leads on the muscle & body-composition axis (1.0/5).

Which has more research, GHK-Cu or PE 22-28?

GHK-Cu has 5 approved studies indexed (Preclinical); PE 22-28 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack GHK-Cu and PE 22-28?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of GHK-Cu vs PE 22-28?

GHK-Cu: community-reported improved skin texture, localized irritation, transient tingling. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is GHK-Cu or PE 22-28 FDA-approved?

GHK-Cu is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is PE 22-28 better than GHK-Cu?

For metabolic, PE 22-28 has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

GHK-Cu and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.